Adjuvant treatment with Trastuzumab in patients with breast cancer in Uruguay
Breast cancer is the most frequent and the leading cause of death from cancer in women in Uruguay. Trastuzumab is a recombinant humanized monoclonal antibody targeted against the HER2 transmembrane growth factor receptor. RCT phase III had showed its benefit in adjuvant-treatment, associated to chemotherapy, in patients with HER2-positive breast cancer. The treatment with Trastuzumab is funded, with central and universal coverage, for breast cancer patients in Uruguay. A regulatory framework for coverage and a systematic process of evaluation were established.
Autores:
Dr. Henry L. Albornoz Da Silva, Dr. Fernando Correa, Lic. Marcela Baldizzoni, Lic. Isabel Wall, MSc. Gustavo Saona, Dr. Abayuba Perna. Dr. Henry L. Albornoz Da Silva, Dr. Fernando Correa, Lic. Marcela Baldizzoni, Lic. Isabel Wall, MSc. Gustavo Saona, Dr. Abayuba Perna.
Tipo de publicación:
P. CIENTÍFICAS - Póster y Presentaciones